Q/C Technologies, Inc.: 5%+ holders

As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Q/C Technologies, Inc. The largest reported stake is PharmaCyte Biotech, Inc.'s, at 74%. One filing is on record since November 18, 2025 (Schedule 13D/A, November 18, 2025).

Bruce Bernstein is also named on 3 other Form D filings ↓

Sell to companies like Q/C Technologies, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Q/C Technologies, Inc. has 1 Schedule 13D or 13G filing on record since 2025-11-18. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Q/C Technologies, Inc. and the warning signs.

See Q/C Technologies, Inc.'s free Snapshot Watch Q/C Technologies, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Q/C Technologies, Inc. and the records around it.

The people at Q/C Technologies, Inc.

• Bruce Bernstein is also named on 3 other Form D filings: XWELL, Inc. (Mar 2026), Synaptogenix, Inc. (Jun 2025)
• Joshua Silverman is also named on 1 other Form D filing: Synaptogenix, Inc. (Jun 2025)

Q/C Technologies, Inc. elsewhere on the record

• Leadership changes Sep 2026
• Form D filing Sep 2025
• Who owns it

Companies that share a holder

• PharmaCyte Biotech, Inc. also filed stake reports on 1 other company: FEMASYS INC (Mar 2026)

Want the whole picture on Q/C Technologies, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Q/C Technologies, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Q/C Technologies, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   4 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Purpose of Transaction (Item 4)

PharmaCyte Biotech, Inc.

The disclosure provided in Item 4 of the Original Schedule 13D is updated to include the following additional disclosure. On September 2, 2025, the Reporting Person entered into a Securities Purchase Agreement (the "Purchase Agreement") with the Issuer, pursuant to which it agreed to purchase from the Issuer (i) shares of the Issuer's Series H Convertible Preferred Stock (the "Series H Preferred Shares"), convertible into 600,000 shares of Common Stock at an initial conversion price of $5.00 per share, and (ii) warrants with a five-year term from November 14, 2025, the date that the Issuer's stockholders approved the issuance of more than 19.99% of the Issuer's outstanding shares of Common Stock in accordance with Nasdaq listing standards ("Stockholder Approval") to purchase up to 600,000 shares of Common Stock at an exercise price of $5.00 per share (the "Warrants"). Pursuant to the adjustment provisions in the Series H Preferred Shares and the Warrants, the conversion price of the Series H Preferred Shares and the exercise price of the Warrants subsequently adjusted from $5.00 per share to $3.3713 per share and the number of shares of Common Stock issuable to the Reporting Person upon conversion of the Series H Preferred Shares was adjusted proportionally to 889,865 and the number of Warrants was adjusted proportionally to 889,865. The Series H Preferred Shares and Warrants shall be referred to herein as the "Securities," and the Reporting Person's purchase thereof shall …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-11-18; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Also on the record for Q/C Technologies, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Q/C Technologies, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Q/C Technologies, Inc. is mentioned again
• Find former Q/C Technologies, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes